EH3A Amarin Corporation Plc Sponsored ADR

Amarin to Present at the 41st Annual J.P. Morgan Healthcare Conference

Amarin to Present at the 41st Annual J.P. Morgan Healthcare Conference

DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023.

41st Annual J.P. Morgan Healthcare Conference (January 9th-12th, 2023; San Francisco, California)

Date/Time: January 10, 2023, 8:15 p.m. ET/ 5:15 p.m. PST

Webcast: /events/healthcare23/sessions/43879-amarin-corporation-plc/webcast?gpu_only=true&kiosk=true

The conference presentation will be webcast live and archived on the Company’s website in the Investor Relations section under Events and Presentations at  .

About Amarin  

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.  

Availability of Other Information About Amarin

Amarin communicates with its investors and the public using the company website () and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information  

Investor Inquiries:  

Investor Relations  

Amarin Corporation plc  

(investor inquiries) 

Media Inquiries:

Communications  

Amarin Corporation plc  

(media inquiries)  



EN
14/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amarin Corporation Plc Sponsored ADR

 PRESS RELEASE

Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Man...

Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline DUBLIN and BRIDGEWATER, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin”), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the recommendation that the treatment of CV risk in patients with hypertriglyceridemia be part of a broader dyslipidemia management as discussed in the 2026 American College of Cardiology (ACC) / American Hea...

 PRESS RELEASE

New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In V...

New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo DUBLIN and BRIDGEWATER, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced that additional REDUCE-IT patient subgroup analysis and additional mechanistic data on potential multifactorial bi...

 PRESS RELEASE

Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations an...

Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology Peer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of IPE on patient-centered measures of total disease burden DUBLIN and BRIDGEWATER, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascula...

 PRESS RELEASE

Amarin Reports Fourth Quarter and Full Year 2025 Financial Results

Amarin Reports Fourth Quarter and Full Year 2025 Financial Results Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge Supported in 2025 DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a c...

 PRESS RELEASE

This American Heart Month Amarin Spotlights the Need to Prioritize Pro...

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease DUBLIN and BRIDGEWATER, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today issued a call to action for American Heart Month emphasizing a message that cannot wait: the United States has an opportunity to significantly reduce heart attacks, strokes, and cardiovascular deaths by prioritizing the use of proven,...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch